Sentinel node biopsy in breast cancer: results in a large series

Detalhes bibliográficos
Autor(a) principal: Carvalho,S.M.T.
Data de Publicação: 2010
Outros Autores: Mourão Netto,M., Lima,E.N.P., Pimentel,A.M., Makdissi,F.B., Osório,C.A.B.T., Maciel,M.S., Iyeyasu,H., Collins,J.B., Fontes,C.M., Perina,A.L., Soares,F.A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600011
Resumo: Sentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of blue dye or radiolabeled 99mTc-Dextran-500, or both. Of these 1154 patients, 857 were N0(i-) (no regional lymph node metastasis, negative immunohistochemistry, IHC), 96 were N0(i+) (no regional lymph node metastasis histologically, positive IHC, no IHC cluster greater than 0.2 mm) and 201 were N1mi (greater than 0.2 mm, none greater than 2.0 mm). Most of the tumors (70%) were invasive ductal carcinomas and tumors were staged as T1 in 770 patients (65%). A total of 274 patients underwent SLNB and axillary dissections up to April 2003. The inclusion criteria were tumor size equal to or less than 3 cm in diameter, no clinically palpable axillary lymph nodes, no neoadjuvant therapy. In 19 cases, the SLN could not be identified intraoperatively. A false-negative rate of 11% and a negative predictive value of 88.2% were obtained for the 255 assessable patients. The overall concordance between SLNB and axillary lymph node status was 92%. SLNB sensitivity for nodes was 81% and specificity was 100%. The higher sensitivity, specificity, accuracy, and lower false-negative rates of SLNB suggest that this method may be an appropriate alternative to total axillary dissection in early breast cancer patients.
id ABDC-1_18e1e2b58df73eaa6c5baff34f00fbb6
oai_identifier_str oai:scielo:S0100-879X2010000600011
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling Sentinel node biopsy in breast cancer: results in a large seriesBreast neoplasmsSentinel lymph nodeSentinel lymph node biopsyCompletion axillary dissectionSentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of blue dye or radiolabeled 99mTc-Dextran-500, or both. Of these 1154 patients, 857 were N0(i-) (no regional lymph node metastasis, negative immunohistochemistry, IHC), 96 were N0(i+) (no regional lymph node metastasis histologically, positive IHC, no IHC cluster greater than 0.2 mm) and 201 were N1mi (greater than 0.2 mm, none greater than 2.0 mm). Most of the tumors (70%) were invasive ductal carcinomas and tumors were staged as T1 in 770 patients (65%). A total of 274 patients underwent SLNB and axillary dissections up to April 2003. The inclusion criteria were tumor size equal to or less than 3 cm in diameter, no clinically palpable axillary lymph nodes, no neoadjuvant therapy. In 19 cases, the SLN could not be identified intraoperatively. A false-negative rate of 11% and a negative predictive value of 88.2% were obtained for the 255 assessable patients. The overall concordance between SLNB and axillary lymph node status was 92%. SLNB sensitivity for nodes was 81% and specificity was 100%. The higher sensitivity, specificity, accuracy, and lower false-negative rates of SLNB suggest that this method may be an appropriate alternative to total axillary dissection in early breast cancer patients.Associação Brasileira de Divulgação Científica2010-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600011Brazilian Journal of Medical and Biological Research v.43 n.6 2010reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2010007500048info:eu-repo/semantics/openAccessCarvalho,S.M.T.Mourão Netto,M.Lima,E.N.P.Pimentel,A.M.Makdissi,F.B.Osório,C.A.B.T.Maciel,M.S.Iyeyasu,H.Collins,J.B.Fontes,C.M.Perina,A.L.Soares,F.A.eng2010-06-07T00:00:00Zoai:scielo:S0100-879X2010000600011Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2010-06-07T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv Sentinel node biopsy in breast cancer: results in a large series
title Sentinel node biopsy in breast cancer: results in a large series
spellingShingle Sentinel node biopsy in breast cancer: results in a large series
Carvalho,S.M.T.
Breast neoplasms
Sentinel lymph node
Sentinel lymph node biopsy
Completion axillary dissection
title_short Sentinel node biopsy in breast cancer: results in a large series
title_full Sentinel node biopsy in breast cancer: results in a large series
title_fullStr Sentinel node biopsy in breast cancer: results in a large series
title_full_unstemmed Sentinel node biopsy in breast cancer: results in a large series
title_sort Sentinel node biopsy in breast cancer: results in a large series
author Carvalho,S.M.T.
author_facet Carvalho,S.M.T.
Mourão Netto,M.
Lima,E.N.P.
Pimentel,A.M.
Makdissi,F.B.
Osório,C.A.B.T.
Maciel,M.S.
Iyeyasu,H.
Collins,J.B.
Fontes,C.M.
Perina,A.L.
Soares,F.A.
author_role author
author2 Mourão Netto,M.
Lima,E.N.P.
Pimentel,A.M.
Makdissi,F.B.
Osório,C.A.B.T.
Maciel,M.S.
Iyeyasu,H.
Collins,J.B.
Fontes,C.M.
Perina,A.L.
Soares,F.A.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Carvalho,S.M.T.
Mourão Netto,M.
Lima,E.N.P.
Pimentel,A.M.
Makdissi,F.B.
Osório,C.A.B.T.
Maciel,M.S.
Iyeyasu,H.
Collins,J.B.
Fontes,C.M.
Perina,A.L.
Soares,F.A.
dc.subject.por.fl_str_mv Breast neoplasms
Sentinel lymph node
Sentinel lymph node biopsy
Completion axillary dissection
topic Breast neoplasms
Sentinel lymph node
Sentinel lymph node biopsy
Completion axillary dissection
description Sentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of blue dye or radiolabeled 99mTc-Dextran-500, or both. Of these 1154 patients, 857 were N0(i-) (no regional lymph node metastasis, negative immunohistochemistry, IHC), 96 were N0(i+) (no regional lymph node metastasis histologically, positive IHC, no IHC cluster greater than 0.2 mm) and 201 were N1mi (greater than 0.2 mm, none greater than 2.0 mm). Most of the tumors (70%) were invasive ductal carcinomas and tumors were staged as T1 in 770 patients (65%). A total of 274 patients underwent SLNB and axillary dissections up to April 2003. The inclusion criteria were tumor size equal to or less than 3 cm in diameter, no clinically palpable axillary lymph nodes, no neoadjuvant therapy. In 19 cases, the SLN could not be identified intraoperatively. A false-negative rate of 11% and a negative predictive value of 88.2% were obtained for the 255 assessable patients. The overall concordance between SLNB and axillary lymph node status was 92%. SLNB sensitivity for nodes was 81% and specificity was 100%. The higher sensitivity, specificity, accuracy, and lower false-negative rates of SLNB suggest that this method may be an appropriate alternative to total axillary dissection in early breast cancer patients.
publishDate 2010
dc.date.none.fl_str_mv 2010-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010000600011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-879X2010007500048
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.43 n.6 2010
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302938915799040